BioCentury | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

...The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide...
...Co. Ltd. (Tokyo:4523), Tokyo, Japan Fujirebio Inc. , Tokyo, Japan Business: Cancer Jaime De Leon farletuzumab Eisai Co. Ltd. Fujirebio...
BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

...to mutations -- including resistance mutations -- as well as changes in the RNA transcriptome. Fujirebio...
...Exosome Diagnostics Inc. Cambridge, Mass. Exotech Bio Inc., Germantown, Md. Exovita Biosciences Inc., Albuquerque, N.M. Fujirebio...
BioCentury | May 27, 2013
Company News

Cizzle Biotechnology, Fujirebio deal

...Cizzle and Fujirebio's Fujirebio Diagnostics Inc. will co-develop Cizzle's blood test that detects a variant of...
...develop a simplified commercial version of the test that can be used in clinical practice. Fujirebio...
...Cizzle. The companies could not be reached for details. Cizzle Biotechnology Ltd. , York, U.K. Fujirebio...
BioCentury | Apr 15, 2013
Clinical News

ARCHITECT Galectin-3 test regulatory update

...Abbott's Architect platform and other diagnostic instruments (see BioCentury, March 15, 2010). BG Medicine partner Fujirebio...
...ARCHITECT Galectin-3 test after FDA requested additional clinical data information last July. BG Medicine expects Fujirebio...
BioCentury | Apr 1, 2013
Clinical News

ARCHITECT Galectin-3 test regulatory update

...BG Medicine disclosed in its 2012 earnings that partner Fujirebio Inc. (Tokyo, Japan) withdrew a 510(k...
...in assessing the prognosis of patients diagnosed with chronic heart failure (CHF). BG Medicine said Fujirebio...
...Fujirebio to submit a new 510(k) application next half addressing FDA's questions. BG Medicine said Fujirebio...
BioCentury | Dec 3, 2012
Company News

Fujirebio, Thermo Fisher deal

...Thermo Fisher and Fujirebio partnered to make Thermo Fisher's Procalcitonin biomarker assay available on Fujirebio's Lumipulse...
...products use chemiluminescent enzyme immunoassay (CLEIA) technology. The partners could not be reached for comment. Fujirebio...
BioCentury | Jan 23, 2012
Company News

Fujirebio, Laboratory Corp. of American Holdings, Abbott sales and marketing update

...the Risk of Ovarian Malignancy Algorithm (ROMA) stratification tool in the U.S. The tool combines Fujirebio's...
...commercialize automated versions of the test (see BioCentury, Dec. 22, 2008 & Feb. 2, 2009). Fujirebio...
BioCentury | Sep 12, 2011
Clinical News

HE4 enzyme immunoassay regulatory update

...FDA granted 510(k) clearance for Fujirebio's HE4 enzyme immunoassay (EIA) to be used in combination with...
...commercialize automated versions of the test (see BioCentury, Dec. 22, 2008 & Feb. 2, 2009). Fujirebio...
BioCentury | Jun 6, 2011
Clinical News

CYFRA 21-1 EIA assay regulatory update

...Fujirebio's Fujirebio Diagnostics Inc. unit received 510(k) clearance from FDA for its CYFRA 21-1 EIA assay...
...samples is available in the U.S. for $550 for a kit with a 100 tests. Fujirebio...
BioCentury | Nov 8, 2010
Company News

GenMark Diagnostics, Miraca deal

...will use the technology to expand its diagnostic test offerings. Financial terms were not disclosed. Fujirebio...
Items per page:
1 - 10 of 45
BioCentury | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

...The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide...
...Co. Ltd. (Tokyo:4523), Tokyo, Japan Fujirebio Inc. , Tokyo, Japan Business: Cancer Jaime De Leon farletuzumab Eisai Co. Ltd. Fujirebio...
BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

...to mutations -- including resistance mutations -- as well as changes in the RNA transcriptome. Fujirebio...
...Exosome Diagnostics Inc. Cambridge, Mass. Exotech Bio Inc., Germantown, Md. Exovita Biosciences Inc., Albuquerque, N.M. Fujirebio...
BioCentury | May 27, 2013
Company News

Cizzle Biotechnology, Fujirebio deal

...Cizzle and Fujirebio's Fujirebio Diagnostics Inc. will co-develop Cizzle's blood test that detects a variant of...
...develop a simplified commercial version of the test that can be used in clinical practice. Fujirebio...
...Cizzle. The companies could not be reached for details. Cizzle Biotechnology Ltd. , York, U.K. Fujirebio...
BioCentury | Apr 15, 2013
Clinical News

ARCHITECT Galectin-3 test regulatory update

...Abbott's Architect platform and other diagnostic instruments (see BioCentury, March 15, 2010). BG Medicine partner Fujirebio...
...ARCHITECT Galectin-3 test after FDA requested additional clinical data information last July. BG Medicine expects Fujirebio...
BioCentury | Apr 1, 2013
Clinical News

ARCHITECT Galectin-3 test regulatory update

...BG Medicine disclosed in its 2012 earnings that partner Fujirebio Inc. (Tokyo, Japan) withdrew a 510(k...
...in assessing the prognosis of patients diagnosed with chronic heart failure (CHF). BG Medicine said Fujirebio...
...Fujirebio to submit a new 510(k) application next half addressing FDA's questions. BG Medicine said Fujirebio...
BioCentury | Dec 3, 2012
Company News

Fujirebio, Thermo Fisher deal

...Thermo Fisher and Fujirebio partnered to make Thermo Fisher's Procalcitonin biomarker assay available on Fujirebio's Lumipulse...
...products use chemiluminescent enzyme immunoassay (CLEIA) technology. The partners could not be reached for comment. Fujirebio...
BioCentury | Jan 23, 2012
Company News

Fujirebio, Laboratory Corp. of American Holdings, Abbott sales and marketing update

...the Risk of Ovarian Malignancy Algorithm (ROMA) stratification tool in the U.S. The tool combines Fujirebio's...
...commercialize automated versions of the test (see BioCentury, Dec. 22, 2008 & Feb. 2, 2009). Fujirebio...
BioCentury | Sep 12, 2011
Clinical News

HE4 enzyme immunoassay regulatory update

...FDA granted 510(k) clearance for Fujirebio's HE4 enzyme immunoassay (EIA) to be used in combination with...
...commercialize automated versions of the test (see BioCentury, Dec. 22, 2008 & Feb. 2, 2009). Fujirebio...
BioCentury | Jun 6, 2011
Clinical News

CYFRA 21-1 EIA assay regulatory update

...Fujirebio's Fujirebio Diagnostics Inc. unit received 510(k) clearance from FDA for its CYFRA 21-1 EIA assay...
...samples is available in the U.S. for $550 for a kit with a 100 tests. Fujirebio...
BioCentury | Nov 8, 2010
Company News

GenMark Diagnostics, Miraca deal

...will use the technology to expand its diagnostic test offerings. Financial terms were not disclosed. Fujirebio...
Items per page:
1 - 10 of 45